# WEST Search History

updated 1/27/05 VGP

Hide Items | Restore | Clear | Cancel

DATE: Monday, January 24, 2005

| Hide? | Set Name | Query | Hit Count |
|---|---|---|---|
| | | *DB=PGPB; PLUR=YES; OP=AND* | |
| ☐ | L1 | 20040180061 | 1 |
| ☐ | L2 | L1 and skull | 1 |
| ☐ | L3 | L2 and neural and intracranial | 1 |
| ☐ | L4 | l3 and bone | 0 |
| ☐ | L5 | l3 and within | 1 |
| | | *DB=PGPB,USPT; PLUR=YES; OP=AND* | |
| ☐ | L6 | skull.clm. or $cranium.clm. or cranial$.clm. or $cranial.clm. | 2276 |
| ☐ | L7 | L6 and (toxin or $toxin or neurotoxin or neuro-toxin or botox or dysport or botulinum or clostridial or tetanus or tetan$ or btx or btn or botulin or botulinal).clm. | 75 |
| ☐ | L8 | l7 and allergan.asn. | 12 |

END OF SEARCH HISTORY

Summary of Invention Paragraph:
[0074] "Local administration" means direct administration of a pharmaceutical at or to the vicinity of a site on or within an animal body, at which site a biological effect of the pharmaceutical is desired. Local administration excludes systemic routes of administration, such as intravenous or oral administration.

Detail Description Paragraph:

[0084] The present invention is based on the discovery that intracranial administration of a neurotoxin can provide significant and long lasting relief from a variety of different neuropsychiatric disorders. Intracranial administration permits a neurotoxin to be locally administered at a site, within a patient's cranium, that has a direct effect on the neurons involved in the disorders, and avoids complications associated with passage of the neurotoxin across the blood brain barrier. Thus, intracranial administration provides greater local dosages of a neurotoxin to a brain area than is achieved with systemic routes of administration, and avoids the non-specificity associated with systemic administration of current therapeutic agents. Indeed, systemic administration of a neurotoxin, such as a botulinum toxin, is contraindicated due to the severe complications (i.e. botulism) which can result from entry of a botulinum toxin into the patient's general circulation.

DOCUMENT-IDENTIFIER: US 6746669 B1
** See image for Certificate of Correction **
TITLE: Method for down-regulating IL5 activity

CLAIMS:

10. The method according to claim 9, wherein the natural T-helper lymphocyte epitope is selected from a tetanus toxoid epitope, a diptheria toxoid epitope, an influenza virus hemagluttinin epitope, and an epitope of P. falciparum circumsporozoite (CS) protein.

18. The method according to claim 17, wherein the adjuvant is selected from the group consisting of an immune targeting adjuvant; a toxin; a cytokine; a mycobactexial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin, an immunostimulating complex matrix (an ISCOM matrix); a particle; dimethyldioctadecylammonium bromide, aluminium adjuvants; DNA adjuvants; .gamma.-insulin; and an encapsulating adjuvant.

19. The method according to claim 1, wherein an effective amount of the modified IL5 polypeptide is administered to the animal via a route selected from the parenteral route; the peritoneal route; the oral route; the buccal route; the sublinqual route; the epidural route; the spinal route; the anal route; and the intracranial route.

24. The method according to claim 10, wherein the tetanus toxoid epitope is selected from the group consisting of P2 and P30.

34. An immunogenic composition according to claim 33, wherein the adjuvant is selected from the group consisting of an immune targeting adjuvant; a toxin; a cytokine; a mycobacterial derivative; an oil formulation; a polymer, a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (an ISCOM matrix); a particle; dimethyldioctadecylammonium bromide; aluminium adjuvants; DNA adjuvants; .gamma.-inulin; and an encapsulating adjuvant.

(b) injecting the neurotoxin into the subarachnoid space.

31. A method for the in vivo attenuation of a nociceptive activity or experience of a human patient, the method comprising the step of intraspinal administration to a human patient a therapeutically effective amount of a botulinum toxin, wherin the botolinum toxin is not attached to a neuronal targeting moiety thereby causing an in vivo attenuation of a nociceptive activity or experience of the human patient, wherein the botulinum toxin is a recombinantly produced botulinum toxin.

33. The method of claim 31, wherein the botulinum toxin is selected from the group consisting of modified botulinum toxins A, B, C, D, E, F and G.

34. The method of claim 33, wherein the botulinum toxin is a botulinum toxin type A.

35. A method for treating pain, the method comprising the steps of:

(a) selecting a neurotoxin free of any neuronal targeting moiety;

(b) choosing a portion of an intraspinal region of a patient which influences pain;

(c) intraspinally administering an effective amount of the neurotoxin selected, thereby alleviating pain experienced by the patient, wherein the neurotoxin is a recombinant produced botulinum toxin.

36. A method for treating pain, the method comprising the step of administering an effective amount of a pharmaceutical preparation to an intraspinal region or to a dorsal root ganglion of a mammal, thereby alleviating pain experienced by the mammal, wherein the pharmaceutical preparation comprises a neurotoxin which is free of any neuronal targeting moiety and wherein the neurotoxin is a recombinantly produced botulinum toxin.

**Search Results** - Record(s) 51 through 75 of 75 returned.

☐ 51. 6827931. 20 Oct 00; 07 Dec 04. Method for treating endocrine disorders. Donovan; Stephen. 424/94.63; 424/236.1 424/239.1 424/247.1 424/94.1 424/94.6 512/12 512/2. A61K038/48 A61K039/08.

☐ 52. 6780870. 31 Jul 02; 24 Aug 04. Pyrimidine derivatives as selective inhibitors of COX-2. Carter; Malcolm Clive, et al. 514/275; 544/330 544/331 544/332. C07D239/42 C07D401/12 A61K031/505.

☐ 53. 6780869. 16 May 02; 24 Aug 04. Pyrimidine derivatives. Green; Richard Howard, et al. 514/275; 544/330 544/332. C07D239/42 A61K031/505.

☐ 54. 6746669. 21 Apr 00; 08 Jun 04. Method for down-regulating IL5 activity. Klysner; Steen. 424/85.2; 424/184.1 424/198.1 530/350. A61K038/20 C07K014/54.

☐ 55. 6718208. 29 Jul 02; 06 Apr 04. Method and system for nerve stimulation prior to and during a medical procedure. Hill; Michael R. S., et al. 607/9; 607/10. A61N001/36.

☐ 56. 6670323. 10 Nov 00; 30 Dec 03. Reduced side-effect hemoglobin compositions. Looker; Douglas L., et al. 514/6;. C07K014/805 C07K014/00.

☐ 57. 6645500. 15 Sep 99; 11 Nov 03. Method for down-regulating osteoprotegerin ligand activity. Halkier; Torben, et al. 424/185.1; 424/192.1 424/198.1 424/201.1 514/2 530/350. A61K039/00 A61K039/295 A61K038/18 C07K014/51.

☐ 58. 6623742. 17 Sep 01; 23 Sep 03. Methods for treating fibromyalgia. Voet; Martin A.. 424/236.1; 424/247.1 435/71.3 514/12 514/2 530/344 530/350. A61K039/08 C07K014/33.

☐ 59. 6620415. 11 Jul 01; 16 Sep 03. Parkinson's disease treatment. Donovan; Stephen. 424/239.1; 424/197.11 424/234.1 424/236.1 424/408 514/2 514/937 514/963. A61K039/08 A61K039/385 A01N037/18.

☐ 60. 6562318. 26 Jul 99; 13 May 03. Particular agents. Filler; Aaron Gershon. 424/1.29; 424/1.11 424/1.37. A61K051/00 A61M036/14.

☐ 61. 6498166. 30 Aug 01; 24 Dec 02. Pyrazolopyridines. Campbell; Ian Baxter, et al. 514/300; 546/121. A61K031/437 C07D471/04 A61P029/00.

☐ 62. 6333037. 25 May 00; 25 Dec 01. Methods for treating pain with a modified neurotoxin. Aoki; Kei Roger, et al. 424/236.1;. A61K039/08.

☐ 63. 6306403. 14 Jun 00; 23 Oct 01. Method for treating parkinson's disease with a botulinum toxin. Donovan; Stephen. 424/239.1; 424/197.11 424/408 514/2 514/963. A61K039/08 A61K039/385 A01N037/18.

☐ 64. 6299893. 17 Apr 00; 09 Oct 01. Method to reduce hair loss and stimulate hair regrowth. Schwartz; Marvin, et al. 424/422; 424/423 424/70.1 514/14 514/2. A61F013/00.

☐ 65. 6159443. 29 Apr 99; 12 Dec 00. X-ray guided drug delivery. Hallahan; Dennis E.. 424/1.17; 424/9.1 424/93.72 435/320.1 435/455 435/6 536/23.1. A61K051/00 A01N063/00 C12Q001/68

C12N015/63 C07H021/04.

☐ 66. 6113915. 12 Oct 99; 05 Sep 00. Methods for treating pain. Aoki; Kei Roger, et al. 424/236.1; 424/247.1. A61K039/08.

☐ 67. 6103746. 19 Feb 98; 15 Aug 00. Methods and compositions for the protection of mitochondria. Yarosh; Daniel B.. 514/398; 424/9.1. A61K031/415.

☐ 68. 5985822. 08 May 95; 16 Nov 99. Inhibition of glial cell proliferation with N-CAM homophilic peptides. Edelman; Gerald M., et al. 514/2; 514/15 530/300 530/327 530/328 530/350. A61K038/00 C07K005/00.

☐ 69. 5752515. 21 Aug 96; 19 May 98. Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier. Jolesz; Ferenc A., et al. 600/458; 600/411 600/437 604/22. A61B005/00.

☐ 70. 5719185. 23 Oct 95; 17 Feb 98. Use for GABA agonists for treating emesis. Bountra; Charanjit, et al. 514/567;. A61K031/195.

☐ 71. 5714468. 19 Jan 96; 03 Feb 98. Method for reduction of migraine headache pain. Binder; William J.. 514/14; 514/2. A61K038/10 A61K038/04.

☐ 72. 5547964. 17 Mar 94; 20 Aug 96. Medical use for tachykinin antagonists. Hagan; Russell M., et al. 514/329; 514/872. A61K031/445.

☐ 73. 5538982. 30 Jun 94; 23 Jul 96. Medical use for tachykinin antagonists. Hagan; Russell M., et al. 514/305; 514/214.01 514/214.03 514/221 514/317 514/322 514/559 514/561 514/568 514/648 514/650 514/654 514/872. A61K031/44 A61K031/20 A61K031/55 A61K031/135.

☐ 74. 5391081. 13 May 92; 21 Feb 95. Method and apparatus for simulating neuromuscular stimulation during medical surgery. Lampotang; Samsun, et al. 434/262; 434/265 434/267. G09B023/28.

☐ 75. 5352447. 10 Aug 92; 04 Oct 94. Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy. Johnson; Virginia, et al. 424/183.1; 424/832 514/12 514/21 514/8 530/391.7 530/394. A61K039/44 A61K037/04 C07K017/02.

Generate Collection Print

| Terms | Documents |
|---|---|
| L6 and (toxin or $toxin or neurotoxin or neuro-toxin or botox or dysport or botulinum or clostridial or tetanus or tetan$ or btx or btn or botulin or botulinal).clm. | 75 |

Prev Page Next Page Go to

☐ 1. 20040180061. 22 Mar 04. 16 Sep 04. Botulinum toxin therapy for neuropsychiatric disorders. Donovan, Stephen. 424/184.1; A61K039/00 A61K039/38 A61K039/08.

☐ 2. 20040146532. 01 Mar 04. 29 Jul 04. Agents and methods for treating pain. Gil, Daniel W., et al. 424/239.1; A61K039/08.

☐ 3. 20030211121. 10 May 02. 13 Nov 03. Therapeutic treatments for neuropsychiatric disorders. Donovan, Stephen. 424/247.1; A61K039/08.

☐ 4. 20030202990. 22 Apr 03. 30 Oct 03. Intracranial botulinum toxin therapy for focal epilepsy. Donovan, Stephen, et al. 424/239.1; A61K039/08.

☐ 5. 20030054975. 17 Sep 01. 20 Mar 03. Methods for treating fibromyalgia. Voet, Martin A.. 514/2; A61K038/16.

☐ 6. 20020068699. 23 Aug 01. 06 Jun 02. Clostridial toxin derivatives and methods for treating pain. Donovan, Stephen. 514/12; 530/350 A61K039/08 C07K014/33.

☐ 7. 6827931. 20 Oct 00; 07 Dec 04. Method for treating endocrine disorders. Donovan; Stephen. 424/94.63; 424/236.1 424/239.1 424/247.1 424/94.1 424/94.6 512/12 512/2. A61K038/48 A61K039/08.

☐ 8. 6623742. 17 Sep 01; 23 Sep 03. Methods for treating fibromyalgia. Voet; Martin A.. 424/236.1; 424/247.1 435/71.3 514/12 514/2 530/344 530/350. A61K039/08 C07K014/33.

☐ 9. 6620415. 11 Jul 01; 16 Sep 03. Parkinson's disease treatment. Donovan; Stephen. 424/239.1; 424/197.11 424/234.1 424/236.1 424/408 514/2 514/937 514/963. A61K039/08 A61K039/385 A01N037/18.

☐ 10. 6333037. 25 May 00; 25 Dec 01. Methods for treating pain with a modified neurotoxin. Aoki; Kei Roger, et al. 424/236.1;. A61K039/08.

☐ 11. 6306403. 14 Jun 00; 23 Oct 01. Method for treating parkinson's disease with a botulinum toxin. Donovan; Stephen. 424/239.1; 424/197.11 424/408 514/2 514/963. A61K039/08 A61K039/385 A01N037/18.

☐ 12. 6113915. 12 Oct 99; 05 Sep 00. Methods for treating pain. Aoki; Kei Roger, et al. 424/236.1; 424/247.1. A61K039/08.

Generate Collection Print

| Terms | Documents |
|---|---|
| L7 and allergan.asn. | 12 |